Therapeutic evaluation of Tongyang Huoxue Decoction for treating sick sinus syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800018464

Enrollment

Unknown

Registered

2018-09-20

Start date

2018-11-20

Completion date

Unknown

Last updated

2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sick sinus syndrome

Interventions

Tongyang Huoxuefang Grou:Tongyang Huoxuefang Granules (Jiangyin Tianjiang Pharmaceutical Co., Ltd., the drug composition of Astragalus, Aconite, Ginseng, Tiansanqi, Huangjing, etc.) one daily, morning

Theophylline sustained release tablets:Theophylline sustained-release tablets (Lu Xinhua Pharmaceutical, national character number H11020150) 1 piece / time, 2 times a day

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. aged between 20 and 80 years old; 2. More than one resting day, more than one standard ECG recorded sinus heart rate below 50 beats / min and or intermittent sinus block; 3. symptoms of sinus node dysfunction, such as palpitations or chest tightness or dizziness or syncope or fatigue or difficulty breathing; 4. Chinese medicine diagnosis is delayed pulse syndrome, syndrome differentiation is yang deficiency and blood stasis; 5. patients with informed consent and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. resting state standard ECG recorded sinus heart rate below 30 beats / min or sinus arrest > 3 seconds; 2. pregnant or lactating women; allergic and allergic to drugs; 3. combined with severe liver disease, or alanine aminotransferase (ALT) = 2 times normal; severe renal dysfunction; 4. patients with myocardial infarction or stroke or other acute diseases or hematopoietic abnormalities and mental illness in the past 3 months; 5. have identified the cause of paroxysmal syncope; 6. persistent persistent ventricular tachycardia; or drug-induced transient secondary bradycardia 7. subjects who participated in other clinical trials within the past month; Those who have used anti-slow arrhythmia drugs within 81 weeks;

Design outcomes

Primary

Measure	Time frame
Holter's total efficiency;	—

Countries

China

Contacts

Public ContactLiu Ruxiu

Guang'anmen Hospital; China Academy of China Medical Sciences

liuruxiu1@163.com+86 13911463838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026